Immunoglobulin E–Bet v 1 allergen interaction interface (IgE–Bet v 1 interface)

The Immunoglobulin E–Bet v 1 allergen interaction interface is the molecular contact site between IgE antibodies and Bet v 1, the primary allergen found in birch pollen (UniProt P15494) [1]. This interface is central to the pathophysiology of birch pollen allergy, a Type I hypersensitivity reaction where Bet v 1 molecules cross-link IgE antibodies bound to high-affinity FcεRI receptors on mast cells and basophils [2]. This cross-linking event triggers the immediate release of inflammatory mediators such as histamine and leukotrienes, resulting in symptoms of allergic rhinitis and asthma [4]. Modern therapeutic strategies target this interface by using monoclonal antibodies, such as the REGN5713-5714-5715 cocktail, which are designed to bind specifically to Bet v 1 epitopes and mask them from endogenous IgE [3]. By preventing the formation of the IgE–Bet v 1 complex, these drugs inhibit the activation of effector cells and provide a targeted approach to allergy management [2]. This protein-protein interaction (PPI) target is distinct from general anti-IgE therapies like Omalizumab, as it focuses on neutralizing the specific allergen's ability to interact with the immune system [3]. Understanding the structural biology of this interface is critical for developing high-affinity inhibitors that can effectively compete with the polyclonal IgE response found in sensitized patients [2].

Other names

Bet v 1–IgE complexBet v 1 B-cell epitopeBirch pollen allergen–IgE interfaceMajor birch pollen allergen–IgE interaction site

Competitive inhibition of IgE binding to Bet v 1 epitopes and prevention of IgE cross-linking on effector cells